Yafeng Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yafeng Zhou has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Yufeng Jiang
Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, China
6 shared publicationsXiaofei Mei
Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, China
3 shared publications- Yufeng Jiang
Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China
3 shared publications Kuangyi Wang
Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital
2 shared publicationsLiangping Zhao
Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, China
2 shared publicationsTan Chen
Department of Cardiology, Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China
2 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1752485
The gut microbiota: an emerging therapeutic target for ICI-associated myocarditis
Gut microbiota and their metabolites are essential for a wide range of human physiological processes, including inflammation, immunity, and homeostasis. The intricate interplay between gut microbiota and the host immune system profoundly influences both the therapeutic response and the immune-related adverse events (irAEs) in cancer patients undergoing immune checkpoint inhibitors (ICIs) therapy. Prior evidence has established the rationale for modulating the gut microbiota to improve the incidence and prognosis of ICI-associated myocarditis. In the future, we may prevent or treat ICI-associated myocarditis by regulating the gut microbiota through methods such as microbiota transplantation, antibiotic regimens, or probiotic supplements. But there is still a considerable distance between research and clinical practice.
- 19 February 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1752485
Open AccessThe gut microbiota: an emerging therapeutic target for ICI-associated myocarditis
Gut microbiota and their metabolites are essential for a wide range of human physiological processes, including inflammation, immunity, and homeostasis. The intricate interplay between gut microbiota and the host immune system profoundly influences both the therapeutic response and the immune-related adverse events (irAEs) in cancer patients undergoing immune checkpoint inhibitors (ICIs) therapy. Prior evidence has established the rationale for modulating the gut microbiota to improve the incidence and prognosis of ICI-associated myocarditis. In the future, we may prevent or treat ICI-associated myocarditis by regulating the gut microbiota through methods such as microbiota transplantation, antibiotic regimens, or probiotic supplements. But there is still a considerable distance between research and clinical practice.
- 19 January 2026
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 42 (4) , 623-638
Development and validation of a Magnetocardiography-Based nomogram for predicting coronary stenosis in patients with normal resting electrocardiograms
- 19 January 2026
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 42 (4) , 623-638
Development and validation of a Magnetocardiography-Based nomogram for predicting coronary stenosis in patients with normal resting electrocardiograms
- Open Access
- 21 October 2025
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 20 (1) , 1-5
Drug-coated balloon angioplasty for catastrophic left main STEMI in a 24-year-old with antiphospholipid syndrome: a case report
Antiphospholipid syndrome (APS), characterized by antiphospholipid antibody (aPL)-driven thrombosis, is increasingly recognized as a critical etiology of catastrophic coronary events in young adults lacking traditional cardiovascular risk factors. This report delineates a 24-year-old male with left main coronary artery (LMCA) ST-segment elevation myocardial infarction (STEMI), managed through a novel strategy combining drug-coated balloon (DCB) angioplasty and APS-targeted pharmacotherapy (anticoagulation and immunomodulation). The case underscores the necessity of etiological exploration in young STEMI populations and challenges the conventional stent-based revascularization paradigm in hypercoagulable states. One-year follow-up demonstrated sustained patency without recurrent thrombosis, validating the efficacy of pathophysiology-guided interventions.
- 21 October 2025
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 20 (1) , 1-5
Open AccessDrug-coated balloon angioplasty for catastrophic left main STEMI in a 24-year-old with antiphospholipid syndrome: a case report
Antiphospholipid syndrome (APS), characterized by antiphospholipid antibody (aPL)-driven thrombosis, is increasingly recognized as a critical etiology of catastrophic coronary events in young adults lacking traditional cardiovascular risk factors. This report delineates a 24-year-old male with left main coronary artery (LMCA) ST-segment elevation myocardial infarction (STEMI), managed through a novel strategy combining drug-coated balloon (DCB) angioplasty and APS-targeted pharmacotherapy (anticoagulation and immunomodulation). The case underscores the necessity of etiological exploration in young STEMI populations and challenges the conventional stent-based revascularization paradigm in hypercoagulable states. One-year follow-up demonstrated sustained patency without recurrent thrombosis, validating the efficacy of pathophysiology-guided interventions.
- Open Access
- 11 August 2025
- Published by Springer Nature in BMC Medical Genomics
- Vol. 18 (1)
The mitochondrial hub gene UCHL1 May serve as a potential biomarker for diagnosing diabetic cardiomyopathy: a comprehensive integration of biological pathways
Diabetic cardiomyopathy (DCM) is a complex clinical syndrome characterized by cardiac systolic and diastolic dysfunction. Research on the underlying mechanism of mitochondrial dysfunction and the involved genes in patients with DCM is limited. We aimed to explore the hub genes and pathways related to mitochondrial dysfunction that affect the progression of DCM. DCM patient datasets (GSE161052, GSE210611 (test sets) and GSE26887 (validation set) were downloaded from the Gene Expression Omnibus (GEO) database. The identification of the differentially expressed genes (DEGs) was performed using the “limma” R package. Mitochondrial dysfunction-related genes (MDRGs) associated with DCM were obtained from the Molecular Signatures Database (MSigDB). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were carried out to analyse the biological function of mitochondrial dysfunction-related differentially expressed genes (MDRDEGs) via the “ClusterProfiler”, “DOSE”, “org.Hs.eg.db” and “circlize” R packages. The diagnostic value of the hub genes for DCM was confirmed using receiver operating characteristic (ROC) curves in the test and validation groups. Moreover, the functions of the hub genes in the context of DCM were explored via gene set enrichment analysis (GSEA). A protein‒protein interaction (PPI) network of the hub genes was constructed using the GeneMANIA database. Finally, real-time reverse transcription polymerase chain reaction (real-time RT PCR) analysis and western blot analysis were performed to detect the expression levels of UCHL1. A total of 705 DEGs and 122 MDRGs closely related to DCM were identified, and 6 MDRDEGs (AGT, KIT, SLC2A1, SLC2A4, TK2, and UCHL1) were obtained and subjected to GO and KEGG enrichment analyses. ROC curve analysis was performed for the test and validation groups. Only the AUC of UCHL1 reached 1.0 in both the test and validation groups, and UCHL1 was identified as a hub gene in DCM. GSEA revealed that multiple biological pathways were activated or inhibited along with alterations in the expression of UCHL1. PPI network analysis revealed that the hub genes interacted with mainly the ASPSCR1, PTPRU, STXBP3, SOCS6 and UCHL5 proteins. There was a reciprocal regulatory relationship between UCHL1 expression and hsa-miR-181a-5p, hsa-miR-193b-3p, hsa-miR-877-5p and hsa-miR-218-5p levels. Finally, real-time RT PCR and western blot analysis revealed that UCHL1 may be used as a potential diagnostic biomarker of DCM. In this study, 6 mitochondrial dysfunction-related hub genes related to DCM were identified. The mitochondrial hub gene UCHL1 was demonstrated to be a potential diagnostic biomarker for DCM. The online version contains supplementary material available at 10.1186/s12920-025-02199-0.
- 11 August 2025
- Published by Springer Nature in BMC Medical Genomics
- Vol. 18 (1)
Open AccessThe mitochondrial hub gene UCHL1 May serve as a potential biomarker for diagnosing diabetic cardiomyopathy: a comprehensive integration of biological pathways
Diabetic cardiomyopathy (DCM) is a complex clinical syndrome characterized by cardiac systolic and diastolic dysfunction. Research on the underlying mechanism of mitochondrial dysfunction and the involved genes in patients with DCM is limited. We aimed to explore the hub genes and pathways related to mitochondrial dysfunction that affect the progression of DCM. DCM patient datasets (GSE161052, GSE210611 (test sets) and GSE26887 (validation set) were downloaded from the Gene Expression Omnibus (GEO) database. The identification of the differentially expressed genes (DEGs) was performed using the “limma” R package. Mitochondrial dysfunction-related genes (MDRGs) associated with DCM were obtained from the Molecular Signatures Database (MSigDB). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were carried out to analyse the biological function of mitochondrial dysfunction-related differentially expressed genes (MDRDEGs) via the “ClusterProfiler”, “DOSE”, “org.Hs.eg.db” and “circlize” R packages. The diagnostic value of the hub genes for DCM was confirmed using receiver operating characteristic (ROC) curves in the test and validation groups. Moreover, the functions of the hub genes in the context of DCM were explored via gene set enrichment analysis (GSEA). A protein‒protein interaction (PPI) network of the hub genes was constructed using the GeneMANIA database. Finally, real-time reverse transcription polymerase chain reaction (real-time RT PCR) analysis and western blot analysis were performed to detect the expression levels of UCHL1. A total of 705 DEGs and 122 MDRGs closely related to DCM were identified, and 6 MDRDEGs (AGT, KIT, SLC2A1, SLC2A4, TK2, and UCHL1) were obtained and subjected to GO and KEGG enrichment analyses. ROC curve analysis was performed for the test and validation groups. Only the AUC of UCHL1 reached 1.0 in both the test and validation groups, and UCHL1 was identified as a hub gene in DCM. GSEA revealed that multiple biological pathways were activated or inhibited along with alterations in the expression of UCHL1. PPI network analysis revealed that the hub genes interacted with mainly the ASPSCR1, PTPRU, STXBP3, SOCS6 and UCHL5 proteins. There was a reciprocal regulatory relationship between UCHL1 expression and hsa-miR-181a-5p, hsa-miR-193b-3p, hsa-miR-877-5p and hsa-miR-218-5p levels. Finally, real-time RT PCR and western blot analysis revealed that UCHL1 may be used as a potential diagnostic biomarker of DCM. In this study, 6 mitochondrial dysfunction-related hub genes related to DCM were identified. The mitochondrial hub gene UCHL1 was demonstrated to be a potential diagnostic biomarker for DCM. The online version contains supplementary material available at 10.1186/s12920-025-02199-0.
- Open Access
- 31 March 2025
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 66 (2) , 285-292
Correlation Between Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism and the Co-Occurrence of Left Ventricular Hypertrophy in Patients with Hypertension
The aim of this study was to explore the association between angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism in the 16th intron and the occurrence of left ventricular hypertrophy (LVH) in hypertensive individuals.This study included 269 patients with hypertension from Dushu Lake Hospital Affiliated to Soochow University who underwent echocardiographic examinations. Among them, 55 patients had hypertension combined with LVH, while 214 patients with hypertension did not have LVH, serving as the case and control groups, respectively. Polymerase chain reaction-restriction fragment length polymorphism was used to perform genetic testing for hypertension in all 269 patients. The Hardy-Weinberg equilibrium test was used to assess genetic equilibrium. The differences in genotype frequencies between the case and control groups were analyzed using the chi-square test. All statistical analyses were performed using SPSS software (version 27.0.1), with statistical significance set at P < 0.05.Genotype distribution in the case and control groups conformed to the Hardy-Weinberg equilibrium (P > 0.05). There was a significant difference in genotype distribution between the case and control groups.Conclusion: ACE gene polymorphism is associated with an increased risk of hypertension combined with LVH.
- 31 March 2025
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 66 (2) , 285-292
Open AccessCorrelation Between Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism and the Co-Occurrence of Left Ventricular Hypertrophy in Patients with Hypertension
The aim of this study was to explore the association between angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism in the 16th intron and the occurrence of left ventricular hypertrophy (LVH) in hypertensive individuals.This study included 269 patients with hypertension from Dushu Lake Hospital Affiliated to Soochow University who underwent echocardiographic examinations. Among them, 55 patients had hypertension combined with LVH, while 214 patients with hypertension did not have LVH, serving as the case and control groups, respectively. Polymerase chain reaction-restriction fragment length polymorphism was used to perform genetic testing for hypertension in all 269 patients. The Hardy-Weinberg equilibrium test was used to assess genetic equilibrium. The differences in genotype frequencies between the case and control groups were analyzed using the chi-square test. All statistical analyses were performed using SPSS software (version 27.0.1), with statistical significance set at P < 0.05.Genotype distribution in the case and control groups conformed to the Hardy-Weinberg equilibrium (P > 0.05). There was a significant difference in genotype distribution between the case and control groups.Conclusion: ACE gene polymorphism is associated with an increased risk of hypertension combined with LVH.
- Open Access
- 12 February 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-14
Exploring the impact of angiotensin-converting enzyme (ACE) gene polymorphism on early diastolic function in hypertension using four-dimensional echocardiography
This study explores the relationship between angiotensin-converting enzyme (ACE) gene polymorphisms and early diastolic dysfunction in patients with hypertension utilizing four-dimensional echocardiography and assesses the prognosis. This study consecutively selected 470 patients with hypertension who visited the Fourth Affiliated Hospital of Soochow University between September 2021 and August 2022, with 274 meeting the inclusion criteria. Hypertension gene testing was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) techniques, and the Hardy–Weinberg equilibrium test was used to confirm genetic equilibrium. Patients were categorized into the D allele group (n = 163) and the non-D allele group (n = 111). Diastolic function was assessed using four-dimensional echocardiography, which included averaging the E/e’ ratio over three cardiac cycles, measuring the left atrial (LA) maximum volume index (LA volume), tricuspid regurgitation velocity (TR velocity), LA strain, and left ventricular isovolumic relaxation time (IVRT). Patients were subsequently classified into the diastolic dysfunction group (n = 133) and the normal diastolic function group (n = 141). Chi-square tests were used to analyze differences in diastolic function indicators between the groups, Logistic regression was applied to control for potential confounding factors, and receiver operating characteristic (ROC) curves were plotted to assess the predictive value of different ACE alleles for diastolic dysfunction in patients with hypertension. The genotype distribution in both the D allele group and the non-D allele group was consistent with Hardy–Weinberg equilibrium (P > 0.05). Compared to the non-D allele group, echocardiographic indicators in the D allele group showed a decline in diastolic function: the average E/e' ratio over three cardiac cycles (14.67 [13.82, 15.80] vs. 9.30 [8.12, 12.00]), LA volume (32.76 [29.34, 34.61] vs. 25.61 [22.63, 29.64] ml/m2), TR velocity (2.90 [2.40, 2.90] vs. 1.40 [1.10, 2.40] cm/s), LA strain (18.00 [14.00, 25.00] vs. 37.00 [24.00, 40.00] %), and IVRT (104.25 [95.87, 106.25] vs. 88.09 [80.99, 96.56] ms). Differences between each group were statistically significant (all P < 0.05). The number of patients with diastolic dysfunction was higher in the D allele group (n = 102; 62.6%) compared to the non-D allele group (n = 31; 27.9%). In the logistic regression model, the D allele was associated with an increased risk of early diastolic dysfunction in hypertension (OR = 4.32, 95% CI = 2.56–7.27, P < 0.01). In the adjusted model, the D allele remained associated with an elevated risk of early diastolic dysfunction in hypertension (OR = 3.83, 95% CI = 2.24–6.54, P < 0.01). ROC curve analysis indicated that the D allele has predictive value for early diastolic dysfunction in patients with hypertension (area under the curve [AUC], 0.667; 95% confidence interval [CI], 0.608–0.723; sensitivity, 76.7%; and specificity, 56.7%; P < 0.05). The ACE-D allele is associated with early diastolic dysfunction in hypertension. ACE gene testing can enhance the predictive value for diastolic dysfunction in patients with hypertension.
- 12 February 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-14
Open AccessExploring the impact of angiotensin-converting enzyme (ACE) gene polymorphism on early diastolic function in hypertension using four-dimensional echocardiography
This study explores the relationship between angiotensin-converting enzyme (ACE) gene polymorphisms and early diastolic dysfunction in patients with hypertension utilizing four-dimensional echocardiography and assesses the prognosis. This study consecutively selected 470 patients with hypertension who visited the Fourth Affiliated Hospital of Soochow University between September 2021 and August 2022, with 274 meeting the inclusion criteria. Hypertension gene testing was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) techniques, and the Hardy–Weinberg equilibrium test was used to confirm genetic equilibrium. Patients were categorized into the D allele group (n = 163) and the non-D allele group (n = 111). Diastolic function was assessed using four-dimensional echocardiography, which included averaging the E/e’ ratio over three cardiac cycles, measuring the left atrial (LA) maximum volume index (LA volume), tricuspid regurgitation velocity (TR velocity), LA strain, and left ventricular isovolumic relaxation time (IVRT). Patients were subsequently classified into the diastolic dysfunction group (n = 133) and the normal diastolic function group (n = 141). Chi-square tests were used to analyze differences in diastolic function indicators between the groups, Logistic regression was applied to control for potential confounding factors, and receiver operating characteristic (ROC) curves were plotted to assess the predictive value of different ACE alleles for diastolic dysfunction in patients with hypertension. The genotype distribution in both the D allele group and the non-D allele group was consistent with Hardy–Weinberg equilibrium (P > 0.05). Compared to the non-D allele group, echocardiographic indicators in the D allele group showed a decline in diastolic function: the average E/e' ratio over three cardiac cycles (14.67 [13.82, 15.80] vs. 9.30 [8.12, 12.00]), LA volume (32.76 [29.34, 34.61] vs. 25.61 [22.63, 29.64] ml/m2), TR velocity (2.90 [2.40, 2.90] vs. 1.40 [1.10, 2.40] cm/s), LA strain (18.00 [14.00, 25.00] vs. 37.00 [24.00, 40.00] %), and IVRT (104.25 [95.87, 106.25] vs. 88.09 [80.99, 96.56] ms). Differences between each group were statistically significant (all P < 0.05). The number of patients with diastolic dysfunction was higher in the D allele group (n = 102; 62.6%) compared to the non-D allele group (n = 31; 27.9%). In the logistic regression model, the D allele was associated with an increased risk of early diastolic dysfunction in hypertension (OR = 4.32, 95% CI = 2.56–7.27, P < 0.01). In the adjusted model, the D allele remained associated with an elevated risk of early diastolic dysfunction in hypertension (OR = 3.83, 95% CI = 2.24–6.54, P < 0.01). ROC curve analysis indicated that the D allele has predictive value for early diastolic dysfunction in patients with hypertension (area under the curve [AUC], 0.667; 95% confidence interval [CI], 0.608–0.723; sensitivity, 76.7%; and specificity, 56.7%; P < 0.05). The ACE-D allele is associated with early diastolic dysfunction in hypertension. ACE gene testing can enhance the predictive value for diastolic dysfunction in patients with hypertension.
- 12 June 2024
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 24 (8) , 836-841
The potential Role of CYP2D6*10(c.100 C>T) Gene Polymorphism in Kidney Injury of Patients with Hypertension Complicated with Non-Elevated Cystatin C
This study aims to investigate the potential role of CYP2D6*10 (c.100 C>T) gene polymorphism in renal function injury among hypertensive patients without elevated cystatin C. A cohort of hypertensive patients without elevated cystatin C was enrolled between 2021 and 2024 in the Fourth Affiliated Hospital of Soochow University, and their peripheral venous blood was used for total RNA extraction and CYP2D6*10 genotype analysis. Based on kidney injury status, patients were categorized into two groups, hypertensive patients with kidney injury (n = 94) and those without (n = 893). General characteristics such as age, gender and hyperlipemia were compared between the two groups. Multiple genotype models were investigated between the two groups, including allele models, dominant models, recessive models, co-dominant models, and super-dominant models. The results revealed that in the co-dominant gene model (CC vs. CT vs. TT), the risk of hypertension combined with renal injury was lower with the CT genotype compared to the CC genotype (Odds Ratio (OR) = 0.55, 95% Confidence Interval (CI) = 0.32–0.93, p = 0.02). In the overdominance model (CC + TT vs. CT), the risk of hypertension and renal injury in CC and CT genotypes was 0.42 times lower than that in the CT genotype (OR = 0.42, 95% CI = 0.27–0.64, p < 0.001). This study proposes CYP2D610 gene polymorphism as a potential predictor of renal function injury in hypertensive patients with normal cystatin C levels. Graphical Abstract
- 12 June 2024
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 24 (8) , 836-841
The potential Role of CYP2D6*10(c.100 C>T) Gene Polymorphism in Kidney Injury of Patients with Hypertension Complicated with Non-Elevated Cystatin C
This study aims to investigate the potential role of CYP2D6*10 (c.100 C>T) gene polymorphism in renal function injury among hypertensive patients without elevated cystatin C. A cohort of hypertensive patients without elevated cystatin C was enrolled between 2021 and 2024 in the Fourth Affiliated Hospital of Soochow University, and their peripheral venous blood was used for total RNA extraction and CYP2D6*10 genotype analysis. Based on kidney injury status, patients were categorized into two groups, hypertensive patients with kidney injury (n = 94) and those without (n = 893). General characteristics such as age, gender and hyperlipemia were compared between the two groups. Multiple genotype models were investigated between the two groups, including allele models, dominant models, recessive models, co-dominant models, and super-dominant models. The results revealed that in the co-dominant gene model (CC vs. CT vs. TT), the risk of hypertension combined with renal injury was lower with the CT genotype compared to the CC genotype (Odds Ratio (OR) = 0.55, 95% Confidence Interval (CI) = 0.32–0.93, p = 0.02). In the overdominance model (CC + TT vs. CT), the risk of hypertension and renal injury in CC and CT genotypes was 0.42 times lower than that in the CT genotype (OR = 0.42, 95% CI = 0.27–0.64, p < 0.001). This study proposes CYP2D610 gene polymorphism as a potential predictor of renal function injury in hypertensive patients with normal cystatin C levels. Graphical Abstract
- Open Access
- 24 July 2023
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 28 (7) , 146
Association between AGTR1 (c.1166 A>C) Polymorphisms and Kidney Injury in Hypertension
Background: High blood pressure is the main cause of cardiovascular diseases. Kidney damage is one of the most common organ secondary damage to hypertension. The study of hypertension gene polymorphisms is an important means of precision treatment of primary hypertension. Objectives: The objective of this study was to explore the relationship between AGTR1 (c.1166 A>C) gene polymorphisms and hypertension combined with kidney damage, while exploring the relationship between codominant, dominant and recessive gene model and hypertension with kidney injury and the susceptibility of different genotypes to hypertension with kidney injury. Methods: The distribution of AGTR1 polymorphism in the AGTR1 in hypertensive patients (hypertension group, 292 patients) and hypertension with kidney injury patients (44 patients) were detected and compared by PCR-melting curve method. Results: The genotype distribution of hypertension and combined groups met Hardy-Weinberg equilibrium (p > 0.05); the distribution difference between the three genotypes was statistically significant (p < 0.05), the codominant, dominant and recessive distribution frequency of genotypes (p < 0.05), and no difference between A allele and C allele (p > 0.05). Conclusions: Our study identified the relationship of AGTRA (c.1166 A>C) with hypertension combined with renal injury, and compared the susceptibility of different genetic models, which may provide novel targets for precision gene therapy of hypertension. Clinical Trial Registration: URL: https://www.chictr.org.cn/indexEN.html; Unique identifier: ChiCTR2100051472.
- 24 July 2023
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 28 (7) , 146
Open AccessAssociation between AGTR1 (c.1166 A>C) Polymorphisms and Kidney Injury in Hypertension
Background: High blood pressure is the main cause of cardiovascular diseases. Kidney damage is one of the most common organ secondary damage to hypertension. The study of hypertension gene polymorphisms is an important means of precision treatment of primary hypertension. Objectives: The objective of this study was to explore the relationship between AGTR1 (c.1166 A>C) gene polymorphisms and hypertension combined with kidney damage, while exploring the relationship between codominant, dominant and recessive gene model and hypertension with kidney injury and the susceptibility of different genotypes to hypertension with kidney injury. Methods: The distribution of AGTR1 polymorphism in the AGTR1 in hypertensive patients (hypertension group, 292 patients) and hypertension with kidney injury patients (44 patients) were detected and compared by PCR-melting curve method. Results: The genotype distribution of hypertension and combined groups met Hardy-Weinberg equilibrium (p > 0.05); the distribution difference between the three genotypes was statistically significant (p < 0.05), the codominant, dominant and recessive distribution frequency of genotypes (p < 0.05), and no difference between A allele and C allele (p > 0.05). Conclusions: Our study identified the relationship of AGTRA (c.1166 A>C) with hypertension combined with renal injury, and compared the susceptibility of different genetic models, which may provide novel targets for precision gene therapy of hypertension. Clinical Trial Registration: URL: https://www.chictr.org.cn/indexEN.html; Unique identifier: ChiCTR2100051472.
- Open Access
- 2 February 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 442
The Interaction of Gut Microbiota and Heart Failure with Preserved Ejection Fraction: From Mechanism to Potential Therapies
Heart failure with preserved ejection fraction (HFpEF) is a disease for which there is no definite and effective treatment, and the number of patients is more than 50% of heart failure (HF) patients. Gut microbiota (GMB) is a general term for a group of microbiota living in humans’ intestinal tracts, which has been proved to be related to cardiovascular diseases, including HFpEF. In HFpEF patients, the composition of GMB is significantly changed, and there has been a tendency toward dysbacteriosis. Metabolites of GMB, such as trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs) and bile acids (BAs) mediate various pathophysiological mechanisms of HFpEF. GMB is a crucial influential factor in inflammation, which is considered to be one of the main causes of HFpEF. The role of GMB in its important comorbidity—metabolic syndrome—also mediates HFpEF. Moreover, HF would aggravate intestinal barrier impairment and microbial translocation, further promoting the disease progression. In view of these mechanisms, drugs targeting GMB may be one of the effective ways to treat HFpEF. This review focuses on the interaction of GMB and HFpEF and analyzes potential therapies.
- 2 February 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 442
Open AccessThe Interaction of Gut Microbiota and Heart Failure with Preserved Ejection Fraction: From Mechanism to Potential Therapies
Heart failure with preserved ejection fraction (HFpEF) is a disease for which there is no definite and effective treatment, and the number of patients is more than 50% of heart failure (HF) patients. Gut microbiota (GMB) is a general term for a group of microbiota living in humans’ intestinal tracts, which has been proved to be related to cardiovascular diseases, including HFpEF. In HFpEF patients, the composition of GMB is significantly changed, and there has been a tendency toward dysbacteriosis. Metabolites of GMB, such as trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs) and bile acids (BAs) mediate various pathophysiological mechanisms of HFpEF. GMB is a crucial influential factor in inflammation, which is considered to be one of the main causes of HFpEF. The role of GMB in its important comorbidity—metabolic syndrome—also mediates HFpEF. Moreover, HF would aggravate intestinal barrier impairment and microbial translocation, further promoting the disease progression. In view of these mechanisms, drugs targeting GMB may be one of the effective ways to treat HFpEF. This review focuses on the interaction of GMB and HFpEF and analyzes potential therapies.